azithromycin ophthalmic solution, 1% + Visine® for Contacts®
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Contact Lens Dry Eye
Conditions
Contact Lens Dry Eye
Trial Timeline
Mar 1, 2010 → Nov 1, 2010
NCT ID
NCT01105624About azithromycin ophthalmic solution, 1% + Visine® for Contacts®
azithromycin ophthalmic solution, 1% + Visine® for Contacts® is a approved stage product being developed by Merck for Contact Lens Dry Eye. The current trial status is completed. This product is registered under clinical trial identifier NCT01105624. Target conditions include Contact Lens Dry Eye.
What happened to similar drugs?
1 of 1 similar drugs in Contact Lens Dry Eye were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01105624 | Approved | Completed |
Competing Products
8 competing products in Contact Lens Dry Eye
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Omalizumab + Omalizumab + Placebo | Novartis | Phase 2 | 35 |
| CP-481,715 | Pfizer | Phase 1 | 29 |
| Tablet Methylprednisolone (4 or 16 mg) | Pfizer | Pre-clinical | 26 |
| Rilonacept + Placebo | Regeneron Pharmaceuticals | Phase 2 | 35 |
| Dupilumab | Regeneron Pharmaceuticals | Approved | 47 |
| Adventan® (methylprednisolone aceponate 0,1%) | Bayer | Phase 1 | 26 |
| rHuPH20 + Placebo | Halozyme Therapeutics | Phase 2 | 32 |
| Bilastine + Bilastine | Faes Farma | Phase 2/3 | 32 |